BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

All News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
9.55 ^CNY	+3.80%		-6.56%	-20.28%

May. 06	Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	CI
Apr. 26	Biocytogen Pharmaceuticals' Loss Narrows in 2023	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	May. 06	CI
Biocytogen Pharmaceuticals' Loss Narrows in 2023	Apr. 26	MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates	Mar. 26	AQ
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	Mar. 25	CI
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc	Feb. 19	CI
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	Jan. 24	AQ
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics	Jan. 23	CI
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	Jan. 09	AQ
Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug	Jan. 08	MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	Jan. 08	CI
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	Dec. 28	AQ
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	Dec. 27	CI
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	Dec. 20	AQ
Biocytogen Strikes Multi-Target Antibody Deal With Neurocrine Biosciences	Dec. 20	MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	Dec. 19	CI
Biocytogen Pharmaceuticals (Beijing) signs antibody evaluation, option and license agreement with Ona Therapeutics	Dec. 19	AQ
Biocytogen, Ona Therapeutics Sign Agreement for Development of Antibody-Drug Conjugates	Dec. 18	MT
Biocytogen Pharmaceuticals Co., Ltd. Announce an Antibody Evaluation, Option and License Agreement with Ona Therapeutics	Dec. 18	CI
Biocytogen Pharmaceuticals Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company	Dec. 12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

All News

Filters